Melphalan

Chemical formula: C₁₃H₁₈Cl₂N₂O₂ Molecular mass: 305.2 g/mol PubChem compound: 460612

Therapeutic indications

Melphalan is indicated for:

Multiple myeloma

Population group: only adults (18 years old or older)

High-dose of melphalan used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of multiple myeloma.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

0.15 mg/kg bodyweight/day in divided doses for 4 days repeated at intervals of six weeks

100-200 mg/m² body surface area once

Ovarian cancer

Population group: women, only adults (18 years old or older)

High-dose of melphalan used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of ovarian cancer.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

0.2 mg/kg bodyweight/day for 5 days every 4-8 weeks

100-200 mg/m² body surface area once

Polycythemia vera

Population group: only adults (18 years old or older)

Melphalan is effective in the treatment of a proportion of patients suffering from polycythaemia vera.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

6-10 mg daily for 5-7 days followed by 2-4 mg daily

Mammary adenocarcinoma

Population group: only adults (18 years old or older)

High-dose of melphalan used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of mammary adenocarcinoma.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

0.15 mg/kg bodyweight or 6 mg/m² body surface area/day for 5 days repeated every 6 weeks

100-200 mg/m² body surface area once

Malignant lymphoma

Population group: only adults (18 years old or older)

High-dose of melphalan used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of malignant lymphoma (Hodgkin, non-Hodgkin lymphoma).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

100-200 mg/m² body surface area once

Acute lymphoblastic and myeloblastic leukemia

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

High-dose of melphalan used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of acute lymphoblastic and myeloblastic leukemia,.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

100-200 mg/m² body surface area once

Malignant haematological diseases before allogeneic haematopoietic stem cell transplantation

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Melphalan in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

140 mg/m² once or 70 mg/m² once daily for 2 consecutive days

140 mg/m² as a single daily infusion

Childhood neuroblastoma

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

High-dose of melphalan used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of childhood neuroblastoma.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

100-200 mg/m² body surface area once

Non-malignant haematological diseases before allogeneic haematopoietic stem cell transplantation

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Melphalan in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as RIC treatment in case of non-malignant haematological diseases.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

140 mg/m² as a single daily infusion or 70 mg/m² once daily for two consecutive days

Contraindications

Melphalan is contraindicated in the following cases:

Lactation

Lactation

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈